重组人p53腺病毒注射液联合顺铂及紫杉醇治疗晚期宫颈癌的效果观察  

Effects of recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel on advanced cervical cancer

作　　者：杨明丽[1] 孙红敏[1] Yang Mingli;Sun Hongmin(Department of Obstetrics and Gynecology,Zhengzhou Third People’s Hospital,Zhengzhou 450000,China)

机构地区：[1]河南省郑州市第三人民医院妇产科,郑州450000

出　　处：《中国实用医刊》2022年第6期89-92,共4页Chinese Journal of Practical Medicine

摘　　要：目的探讨重组人p53腺病毒注射液联合顺铂、紫杉醇治疗晚期宫颈癌的效果。方法抽取2015年10月至2020年10月郑州市第三人民医院收治的晚期宫颈癌患者62例,按照治疗方案分为A组和B组,每组31例。A组采用顺铂、紫杉醇治疗,B组在A组基础上加用重组人p53腺病毒注射液治疗。比较两组疾病控制率、肿瘤变化情况、免疫功能、肿瘤标志物水平[血清鳞状细胞癌抗原(SCC-Ag)、癌胚抗原(CEA)]、不良反应发生率及生存期。结果 B组总控制率为67.74%(21/31),高于A组的41.94%(13/31),差异有统计学意义(P<0.05)。治疗后,B组肿瘤长径小于A组,肿瘤缩小率及CD3+、CD4+水平高于A组,SCC-Ag、CEA水平低于A组(P均<0.05)。B组不良反应发生率为19.35%(6/31),A组为25.81%(8/31),差异未见统计学意义(P>0.05)。B组无进展生存期[(6.35±0.17)个月]长于A组[(4.51±0.13)个月],P<0.05。结论重组人p53腺病毒注射液联合顺铂、紫杉醇治疗晚期宫颈癌,能提高疾病控制率,能改善免疫功能,下调肿瘤标志物表达,延长无进展生存期。Objective To investigate the effects of recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel on advanced cervical cancer.Methods Sixty-two patients with advanced cervical cancer who were admitted to Zhengzhou Third People’s Hospital from October 2015 to October 2020 were selected,and they were divided into group A and group B according to the treatment plans,with 31 cases in each group.Group A was treated with cisplatin and paclitaxel,and group B was treated with recombinant human p53 adenovirus injection based on the treatment of group A.The disease control rate,tumor changes,immune function,tumor marker levels,such as serum squamous cell carcinoma antigen(SCC-Ag)and carcinoembryonic antigen(CEA),incidence of adverse reactions and survival were compared between the two groups.Results The total control rate of group B was 67.74%(21/31),which was significantly higher than 41.94%(13/31)of group A(P<0.05).After treatment,the tumor major diameter of group B was shorter than that of group A,the tumor shrinkage rate,cluster of differentiation 3+(CD3+)and cluster of differentiation 4+(CD4+)levels were higher than those of group A,and the levels of SCC-Ag and CEA were lower than those of group A(all P<0.05).The incidence of adverse reactions was 19.35%(6/31)in group B,and 25.81%(8/31)in group A,and there was no significant difference between the two groups(P>0.05).The progression-free survival time of group B was(6.35±0.17)months,longer than the(4.51±0.13)months of group A(P<0.05).Conclusions Recombinant human p53 adenovirus injection combined with cisplatin and paclitaxel in the treatment of advanced cervical cancer can improve the disease control rate,improve immune function,down-regulate tumor marker expression,and prolong progression-free survival.

关 键 词：宫颈癌 紫杉醇 顺铂 重组人P53腺病毒注射液 

分 类 号：R737.33[医药卫生—肿瘤]